Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to tyrosine kinase inhibitor therapy. We examined the occurrence of treatment-emergent mutations and their impact on response in patients from the ENESTnd phase 3 trial. At the 3-year data cutoff, mutations were de...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Hochhaus, Andreas, Saglio, Giuseppe, Larson, Richard A., Kim, Dong-Wook, Etienne, Gabriel, Rosti, Gianantonio, De Souza, Carmino, Kurokawa, Mineo, Kalaycio, Matt E., Hoenekopp, Albert, Fan, Xiaolin, Shou, Yaping, Kantarjian, Hagop M., Hughes, Timothy P.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2013
Témata:
Myeloid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4915803/
https://ncbi.nlm.nih.gov/pubmed/23502220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-04-423418
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky